A Phase 1 interventional study of BI 1356 BS - single rising dose and BI 1356 BS - multiple rising dose in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-08.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study to examine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356 BS administered to healthy male volunteers at single rising oral doses (1 mg, 2.5 mg, 5 mg, and 10 mg) and at multiple rising oral doses (2.5 mg, 5 mg, and 10 mg once daily for 12 days)
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BI 1356 BS - single rising dose
Drug: BI 1356 BS - multiple rising dose
Drug: Placebo
Number of patients with abnormal findings in physical examination
Time frame: Screening, up to 28 days
Number of patients with clinically significant changes in Vital signs (blood pressure [BP], pulse rate [PR])
Time frame: Screening, up to 28 days
Number of patients with abnormal findings in 12-lead electrocardiogram (ECG)
Time frame: Screening, up to 28 days
Number of patients with abnormal changes in laboratory parameters
Time frame: Screening, up to 28 days
Number of patients with adverse events
Time frame: up to 49 days
Cmax (maximum measured concentration of the analyte in plasma)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
tmax (time from dosing to maximum measured concentration)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
%AUCtz-∞ (the percentage of the AUCtz-∞ that is obtained by extrapolation)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable analyte plasma concentration)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
AUCt1-t2 (area under the concentration-time curve of the analyte in plasma over the time interval from the time point t1 to the time point t2)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
λz (terminal rate constant in plasma)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
t1/2 (terminal half-life of the analyte in plasma)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
MRTpo (mean residence time of the analyte in the body)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
CL/F (apparent clearance of the analyte in plasma after extravascular administration)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
Vz/F (apparent volume of distribution during the terminal phase λz following extravascular administration)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to the time point t2)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
fet1-t2 (fraction of analyte eliminated in urine from the time point t1 to the time point t2)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
CLR,0-24,1 (renal clearance of the analyte from 0 until 24 hours after administration of the first dose)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
Cavg (average concentration of the analyte in plasma at steady state)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
Cpre (predose concentration of the analyte in plasma)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
RA,Cmax based on Cmax
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
RA,AUC based on AUCτ
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
Emin (minimum Dipeptidyl-Peptidase IV (DPP-IV) activity
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
tmin (time to reach minimum DPP-IV activity)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
E24 (DPP-IV activity 24 hours after administration of single dose administration and the first dose of multiple dose administration)
Time frame: up to 192 h (single dose), up to 456 h (multiple dose)
No study locations are listed for this record.
The record gives a start of Jun 2006 and a primary completion of Oct 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linagliptin